Infections in lung cancer patients undergoing immunotherapy and targeted therapy: An overview on the current scenario

被引：10
作者：
Bertaglia, Valentina [1 ]
Morelli, Anna Maria [2 ]
Solinas, Cinzia [3 ]
Aiello, Marco Maria [4 ]
Manunta, Silvia [5 ]
Denaro, Nerina [6 ]
Tampellini, Marco [2 ]
Scartozzi, Mario [3 ]
Novello, Silvia [1 ]
机构：
[1] Univ Turin, San Luigi Gonzaga Hosp, Dept Oncol, I-10043 Orbassano, Torino, Italy
[2] ASL TO3 Osped Infermi, Med Oncol, I-10098 Rivoli, Torino, Italy
[3] Policlin Monserrato, Med Oncol, AOU Cagliari, I-09042 Monserrato, Cagliari, Italy
[4] AOU Policlin Vittorio Emanuele Catania, Med Oncol, I-95100 Catania, Italy
[5] Osped Civile Alghero, Med Oncol, I-07041 Alghero, Italy
[6] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Oncol Dept, I-20122 Milan, Italy
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2023年 / 184卷
关键词：
Non small cell lung cancer; Risk of infections; Immunotherapy; Targeted therapy; IMMUNE CHECKPOINT INHIBITORS; DABRAFENIB PLUS TRAMETINIB; POSITIVE SOLID TUMORS; CHRONIC HEPATITIS-B; OPEN-LABEL; 1ST-LINE TREATMENT; INTEGRATED ANALYSIS; SINGLE-ARM; PHASE-III; MULTICENTER;
D O I：
10.1016/j.critrevonc.2023.103954
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with a diagnosis of lung cancer are often vulnerable to infection, and the risk is increased by tumorassociated immunosuppression and the effects of the treatments. Historically, links between the risk of infection and cytotoxic chemotherapy due to neutropenia and respiratory syndromes are well established. The advent of tyrosine kinase inhibitors (TKIs) and immune-checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)/programmed cell death- ligand 1 (PD-L1) axis and cytotoxic T-lymphocyte antigen-4 (CTLA-4) have changed the treatment paradigm for lung cancer patients. Our understanding of the risk of infections while administrating these drugs is evolving, as are the biological mechanisms that are responsible. In this overview, we focus on the risk of infection with the use of targeted therapies and ICIs, summarizing current evidence from preclinical and clinical studies and discussing their clinical implications.
引用
收藏
页数：17
相关论文
共 110 条
  • [1] Akinosoglou KS, 2013, EUR REV MED PHARMACO, V17, P8
  • [2] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
  • [3] Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
    Bagchi, Sreya
    Yuan, Robert
    Engleman, Edgar G.
    [J]. ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021, 2021, 16 : 223 - 249
  • [4] Restoring function in exhausted CD8 T cells during chronic viral infection
    Barber, DL
    Wherry, EJ
    Masopust, D
    Zhu, BG
    Allison, JP
    Sharpe, AH
    Freeman, GJ
    Ahmed, R
    [J]. NATURE, 2006, 439 (7077) : 682 - 687
  • [5] Barlesi F, 2019, ANN ONCOL, V30, P33
  • [6] Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
    Barlesi, Fabrice
    Vansteenkiste, Johan
    Spigel, David
    Ishii, Hidenobu
    Garassino, Marina
    de Marinis, Filippo
    Ozguroglu, Mustafa
    Szczesna, Aleksandra
    Polychronis, Andreas
    Uslu, Ruchan
    Krzakowski, Maciej
    Lee, Jong-Seok
    Calabro, Luana
    Frontera, Osvaldo Aren
    Ellers-Lenz, Barbara
    Bajars, Marcis
    Ruisi, Mary
    Park, Keunchil
    [J]. LANCET ONCOLOGY, 2018, 19 (11) : 1468 - 1479
  • [7] Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer
    Barriere, Jerome
    Re, Daniel
    Peyrade, Frederic
    Carles, Michel
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 154 : 66 - 72
  • [8] ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
    Bergethon, Kristin
    Shaw, Alice T.
    Ou, Sai-Hong Ignatius
    Katayama, Ryohei
    Lovly, Christine M.
    McDonald, Nerina T.
    Massion, Pierre P.
    Siwak-Tapp, Christina
    Gonzalez, Adriana
    Fang, Rong
    Mark, Eugene J.
    Batten, Julie M.
    Chen, Haiquan
    Wilner, Keith D.
    Kwak, Eunice L.
    Clark, Jeffrey W.
    Carbone, David P.
    Ji, Hongbin
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    Pao, William
    Iafrate, A. John
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : 863 - 870
  • [9] Kinase-targeted cancer therapies: progress, challenges and future directions
    Bhullar, Khushwant S.
    Orrego Lagaron, Naiara
    McGowan, Eileen M.
    Parmar, Indu
    Jha, Amitabh
    Hubbard, Basil P.
    Rupasinghe, H. P. Vasantha
    [J]. MOLECULAR CANCER, 2018, 17
  • [10] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Borghaei, H.
    Paz-Ares, L.
    Horn, L.
    Spigel, D. R.
    Steins, M.
    Ready, N. E.
    Chow, L. Q.
    Vokes, E. E.
    Felip, E.
    Holgado, E.
    Barlesi, F.
    Kohlhaeufl, M.
    Arrieta, O.
    Burgio, M. A.
    Fayette, J.
    Lena, H.
    Poddubskaya, E.
    Gerber, D. E.
    Gettinger, S. N.
    Rudin, C. M.
    Rizvi, N.
    Crino, L.
    Blumenschein, G. R.
    Antonia, S. J.
    Dorange, C.
    Harbison, C. T.
    Finckenstein, F. Graf
    Brahmer, J. R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
12345678910